Algert Global LLC Buys 39,586 Shares of Charles River Laboratories International, Inc. $CRL

Algert Global LLC increased its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 54.0% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 112,870 shares of the medical research company’s stock after purchasing an additional 39,586 shares during the period. Algert Global LLC owned approximately 0.23% of Charles River Laboratories International worth $17,660,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Rothschild Investment LLC boosted its position in shares of Charles River Laboratories International by 82.4% during the third quarter. Rothschild Investment LLC now owns 186 shares of the medical research company’s stock worth $29,000 after buying an additional 84 shares during the period. Neo Ivy Capital Management acquired a new stake in Charles River Laboratories International in the 2nd quarter valued at approximately $29,000. Atlantic Union Bankshares Corp acquired a new stake in Charles River Laboratories International in the 3rd quarter valued at approximately $31,000. Geneos Wealth Management Inc. lifted its stake in Charles River Laboratories International by 98.0% in the 2nd quarter. Geneos Wealth Management Inc. now owns 293 shares of the medical research company’s stock valued at $44,000 after acquiring an additional 145 shares in the last quarter. Finally, Allworth Financial LP boosted its position in Charles River Laboratories International by 172.7% during the 2nd quarter. Allworth Financial LP now owns 300 shares of the medical research company’s stock worth $45,000 after acquiring an additional 190 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Mizuho reduced their price target on Charles River Laboratories International from $215.00 to $175.00 and set a “neutral” rating for the company in a research report on Friday, February 20th. Robert W. Baird set a $193.00 price objective on shares of Charles River Laboratories International in a report on Thursday, February 19th. Morgan Stanley set a $185.00 price objective on shares of Charles River Laboratories International in a research report on Monday, December 1st. Argus set a $200.00 target price on shares of Charles River Laboratories International in a report on Monday, November 17th. Finally, JPMorgan Chase & Co. lifted their price target on shares of Charles River Laboratories International from $165.00 to $190.00 and gave the company a “neutral” rating in a research note on Monday, December 15th. Ten equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Charles River Laboratories International presently has a consensus rating of “Moderate Buy” and a consensus target price of $203.57.

Key Headlines Impacting Charles River Laboratories International

Here are the key news stories impacting Charles River Laboratories International this week:

• Positive Sentiment: Zacks raised its FY2027 EPS view to $11.62 (from $11.30), signaling stronger full‑year outlook and supporting a higher valuation multiple. Zacks FY2027 boost
• Positive Sentiment: Zacks lifted FY2026 EPS to $10.78 (from $10.68), implying near‑term margin or revenue improvement versus prior assumptions. Zacks FY2026 boost
• Positive Sentiment: Zacks published FY2028 EPS of $12.12, reflecting continued expected earnings growth beyond FY2027. Long‑term upgrades can lift investor sentiment. Zacks FY2028 outlook
• Positive Sentiment: Multiple quarterly raises: Q3 2026 to $2.86, Q3 2027 to $3.02, Q4 2026 to $3.02, and Q4 2027 to $3.32 — these sequential upgrades point to improving quarterly momentum. Zacks quarterly upgrades
• Positive Sentiment: Zacks raised mid‑2026 quarterly views (Q2 2026 to $2.85 and Q2/Q3 2026 lifts), indicating expectations for recovery or stronger demand in the upcoming fiscal periods. Zacks mid‑2026 raises
• Neutral Sentiment: Zacks’ estimates differ from the consensus full‑year figure repeatedly cited ($9.36), meaning analyst views remain divergent; the Zacks upgrades imply upside versus consensus but do not change consensus itself. Consensus vs Zacks
• Negative Sentiment: Zacks lowered Q1 2026 EPS from $2.39 to $2.05, a material near‑term cut that could pressure the next quarter’s reported results and short‑term sentiment. Zacks Q1 2026 cut
• Negative Sentiment: Zacks slightly trimmed Q2 2027 to $2.65 (from $2.67), a minor downgrade but another signal of some variability in near‑term cadence. Zacks Q2 2027 trim

Charles River Laboratories International Stock Performance

NYSE CRL opened at $155.61 on Friday. The firm has a market capitalization of $7.66 billion, a P/E ratio of -52.57, a price-to-earnings-growth ratio of 2.66 and a beta of 1.64. The company has a current ratio of 1.29, a quick ratio of 1.02 and a debt-to-equity ratio of 0.67. The firm’s fifty day moving average price is $191.59 and its two-hundred day moving average price is $181.00. Charles River Laboratories International, Inc. has a 1 year low of $91.86 and a 1 year high of $228.88.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 18th. The medical research company reported $2.39 EPS for the quarter, beating analysts’ consensus estimates of $2.33 by $0.06. The company had revenue of $994.23 million during the quarter, compared to the consensus estimate of $986.98 million. Charles River Laboratories International had a negative net margin of 3.59% and a positive return on equity of 15.60%. The company’s quarterly revenue was down .8% on a year-over-year basis. During the same quarter last year, the firm posted $2.66 EPS. Charles River Laboratories International has set its FY 2026 guidance at 10.700-11.200 EPS. As a group, research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc is a leading provider of research models and preclinical and clinical support services for the pharmaceutical, biotechnology and medical device industries. The company’s core offerings include discovery, safety assessment, toxicology, and pathology services, as well as supply of laboratory animals and related diagnostics. Services extend across in vivo and in vitro testing, biologics testing, and support for advanced therapies, helping clients accelerate drug development from early discovery through regulatory submission.

Founded in 1947 in Wilmington, Massachusetts, Charles River has grown through strategic investments and acquisitions to establish a broad portfolio of capabilities.